Recruiting

Observational Study

Sponsor:

UCLA

Code:

NCT04410302

Conditions

Bladder Carcinoma

Gastric Carcinoma

Liver and Intrahepatic Bile Duct Carcinoma

Lung Carcinoma

Malignant Neoplasm

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Study Details

Brief summary:

This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.

Conditions

Bladder Carcinoma

Gastric Carcinoma

Liver and Intrahepatic Bile Duct Carcinoma

Lung Carcinoma

Malignant Neoplasm

Study ID

NCT04410302

Start date

Nov 12, 2019

Status verified date

Jul, 2026

Completion date

Jun, 2027

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric/stomach cancer, and liver cancer)
  • Signed informed consent that will be put on file

Exclusion Criteria:

  • No informed consent obtained
  • Specimen unacceptable/degraded/etc.
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners
  • Adults unable to consent

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Arms

Ancillary-correlative (biospecimen collection)

Patients undergo collection of tumor tissue samples during standard of care tumor biopsy or surgical resection to establish PDXs. Patients may also undergo collection of blood, saliva, and urine samples to compare DNA abnormalities to noncancer cells in order to determine if they were present before the cancer started or developed with it.

Interventions

Biospecimen Collection

Undergo collection of tumor tissue, blood, saliva, and urine samples

Primary outcome measure

  • Establish and characterize at least 200 patient-derived cancer xenografts (PDXs) [ Time Frame: Up to 4 years ]

Central Contacts and Locations

Central contacts

Asst. Clinical Research Coordinator

916-734-1587tfle@ucdavis.edu

Locations

UC Irvine Health/Chao Family Comprehensive Cancer Center

Recruiting

Orange, California, United States, 92868

Contacts

Marian Waterman

949-824-2885marian.waterman@uci.edu

Principal Investigator:

Marian Waterman

University of California Davis Comprehensive Cancer Center

Recruiting

Sacramento, California, United States, 95817

Contacts

Luis G. Carvajal-Carmona

530-752-9654lgcarvajal@ucdavis.edu

Principal Investigator:

Luis G. Carvajal-Carmona

More Information

Sponsor

University of California, Davis

Last update posted

Aug 20, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, Davis on 2026-08-20.